Recurrent thrombosis in patients with antiphospholipid syndrome receiving newer oral anticoagulants: A case report and review of literature

Clinical Medicine and Research

Volumn 15, Issue 1-2, 2017, Pages 41-44

  Joshi, Akanksha ^a   Hong, Jason ^b   Siva, Chokkalingam ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

Author keywords

Anti cardiolipin antibodies; Anti phospholipid Syndrome; Anti 2 glycoprotein antibodies; Anticoagulants; Newer oral anticoagulant; Rivaroxaban; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; WARFARIN; RIVAROXABAN;

ADRENAL HEMORRHAGE; ADULT; ANTIPHOSPHOLIPID SYNDROME; BRONCHOSCOPY; CASE REPORT; CHRONIC KIDNEY FAILURE; DEEP VEIN THROMBOSIS; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM THROMBOSIS; HUMAN; INFERIOR CAVA VEIN; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTOSIS; MEAN CORPUSCULAR VOLUME; MIDDLE AGED; OXYGEN SATURATION; PHYSICAL EXAMINATION; PROTHROMBIN TIME; RECURRENT DISEASE; REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; CHEMICALLY INDUCED; ORAL DRUG ADMINISTRATION; THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; MIDDLE AGED; RIVAROXABAN; THROMBOSIS; WARFARIN;

EID: 85026451069     PISSN: 15394182     EISSN: 15546179     Source Type: Journal    
DOI: 10.3121/cmr.2017.1349     Document Type: Review

References (18)

1. Son M, Wypasek E, Celinska-Lowenhoff M, Undas A. The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases. Thromb Res 2015;135:1035-1036
2. Win K, Rodgers GM. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol 2014;89:1017
3. Schaefer JK, McBane RD, Black DF, Williams LN, Moder KG, Wysokinski WE. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost 2014;112:947-950
4. Signorelli F, Nogueira F, Domingues V, Mariz HA, Levy RA. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol 2016;35:801-805
5. Vergallo R, Aguirre AD, Abtahian F, Minami Y, Soeda T, Chatzizisis YS, Croce K, Jang IK. Recurrent myocardial infarctions and premature coronary atherosclerosis in a 23-year-old man with antiphospholipid syndrome. Thromb Haemost 2016;115:237-239
6. Noel N, Dutasta F, Costedoat-Chalumeau N, Bienvenu B, Mariette X, Geffray L, Sene D, Chaidi RB, Michot JM, Fain O, Darnige L, Ankri A, Cacoub P, Piette JC, Saadoun D. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev 2015;14:680-685
7. Haładyj E, Olesińska M. Rivaroxaban – a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases. Reumatologia 2016;3:146-149
8. Joalland F, de Boysson H, Darnige L, Johnson A, Jeanjean C, Cheze S, Augustin A, Auzary C, Geffray L. Seronegative antiphospholipid syndrome, catastrophic syndrome, new anticoagulants: learning from a difficult case report [article in French]. Rev Med Interne 2014;35:752-756
9. Delgado MG, Rodríguez S, García R, Sánchez P, Sáiz A, Calleja S. Antiphospholipid Syndrome of Late Onset: A Difficult Diagnosis of a Recurrent Embolic Stroke. J Stroke Cerebrovasc Dis 2015;24:e209-e211
10. Rokos J, Heger M, Stöllberger C, Finsterer J, Laufer G, Wiedemann D. Bipolar disorder, ischemic stroke, mitral valve vegetation and recurrent venous thrombosis due to antiphospholipid syndrome despite rivaroxaban. Int J Cardiol 2016;221:383-384
11. Malec K, Góralczyk T, Undas A. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. Thromb Res 2017;152:93-97
12. Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, Levy RA, Ortel TL, Rahman A, Salmon JE, Tektonidou MG, Willis R, Lockshin MD. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014;13:685-696
13. Dufrost V, Risse J, Zuily S, Wahl D. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature. Curr Rheumatol Rep 2016;18:74
14. Cohen H, Hunt BJ, Efthymiou M, Arachchillage DRJ, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Doré CJ, Khamashta M, Isenberg DA; RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, noninferiority trial. Lancet Haematol 2016;3:e426-e436
15. Betancur JF, Bonilla-Abadia F, Hormaza AA, Jaramillo FJ, Canas CA, Tobon GJ. Direct oral anticoagulants in antiphospholipid syndrome: a real life case series. Lupus 2016;25:658-662
16. Kunk P, Macik, B, Rice M. Non-Warfarin Oral Anticoagulants in Anti-Phospholipid Syndrome. Blood 2015;126:1133
17. Sciascia S, Savino S, Breen K, Hunt BJ. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis 2015;26:476-477
18. Pengo V, Banzato A, Bison E, Zoppellaro G, Padayattil Jose S, Denas G. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 2016;25:301-306.